BiotechTube

Ruxolitinib + Enasidenib

Phase 2Completed
0 watching 0 views this week⚡ Active
49
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Accelerated/Blast-phase Myeloproliferative Neoplasm

Conditions

Accelerated/Blast-phase Myeloproliferative Neoplasm, Chronic-phase Myelofibrosis, IDH2 Mutation

Trial Timeline

Jan 14, 2021 → May 30, 2023

NCT ID
NCT04281498

About Ruxolitinib + Enasidenib

Ruxolitinib + Enasidenib is a phase 2 stage product being developed by Incyte for Accelerated/Blast-phase Myeloproliferative Neoplasm. The current trial status is completed. This product is registered under clinical trial identifier NCT04281498. Target conditions include Accelerated/Blast-phase Myeloproliferative Neoplasm, Chronic-phase Myelofibrosis, IDH2 Mutation.

Hype Score Breakdown

Clinical
17
Activity
12
Company
7
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT04281498Phase 2Completed

Other Products from Incyte

ruxolitinib creamApproved
82
Itacitinib + Placebo + Prednisone + MethylprednisolonePhase 3
74
Povorcitinib + PlaceboPhase 3
74
Ruxolitinib Cream + Vehicle CreamPhase 3
74
Tacrolimus (Tac) + Methotrexate (MTX) + Ruxolitinib (Rux) + Cyclophosphamide + Mycophenolate mofetil (MMF)Phase 3
74